Cite
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
MLA
Braegelmann, Johannes, et al. MAPK-Pathway Inhibition Mediates Inflammatory Reprogramming and Sensitizes Tumors to Targeted Activation of Innate Immunity Sensor RIG-I. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1312207640&authtype=sso&custid=ns315887.
APA
Braegelmann, J., Lorenz, C., Borchmann, S., Nishii, K., Wegner, J., Meder, L., Ostendorp, J., Ast, D. F., Heimsoeth, A., Nakasuka, T., Hirabae, A., Okawa, S., Dammert, M. A., Plenker, D., Klein, S., Lohneis, P., Gu, J., Godfrey, L. K., Forster, J., … Sos, M. L. (2021). MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.
Chicago
Braegelmann, Johannes, Carina Lorenz, Sven Borchmann, Kazuya Nishii, Julia Wegner, Lydia Meder, Jenny Ostendorp, et al. 2021. “MAPK-Pathway Inhibition Mediates Inflammatory Reprogramming and Sensitizes Tumors to Targeted Activation of Innate Immunity Sensor RIG-I.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1312207640&authtype=sso&custid=ns315887.